OnDosis proprietary technology delivers flexible and individualized dosing of oral medicines formulated as micro units. They are focused on providing reassurance in disease management, supporting adherence and providing greater convenience for patients. OnDosis is currently developing products for individualized dosing in diseases with asignificant burden on patients and healthcare such as ADHD, pain management and immunosuppression for organ transplants. Hundreds of thousands of patients with these conditions could be helped by improved dosing, ultimately leading to improving health care outcomes.The flexibility of OnDosis technology provides the potential for application across several disease areas and patient segments where conventional tablets or capsules often does not provide a good fit for the patient or treatment goal.OnDosis was founded in 2017 and is headquartered in Gothenburg, Sweden, based on an idea that was spun-out from AstraZeneca, using technology based on development work initiated there. It was founded by GU Ventures and Martin Olovsson. OnDosis operates a network of strategic partners across all core functions including formulation and device development, IP, Regulatory and Business Development.

Pharmaceutical

OnDosis

Martin Olovsson

Stina Wigren

Stefan Kristo

Stéphane Baronnet

Joshua Carney

The Development team at OnDosis is responsible for the conception, design, and creation of the company's innovative dosing technology. This team, led by the Head of Device Development, the Head of Design and Development, and the Tech Lead, focuses on developing and enhancing the micro-unit dosing system for various medical applications. Their work ensures that OnDosis delivers flexible, individualized medication solutions that improve patient outcomes in disease areas such as ADHD, pain management, and immunosuppression for organ transplants.

Development

Engineering Team

Leadership Team

Development

About

Team members

Other teams at OnDosis

Engineering Team

Leadership Team